Evidence map›Paper›PMID 39385035›Full record

ArticleNature2024

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Ana Galan-Cobo, John T Le, Meagan Montesion, Rachael Palmer, Nadine Jahchan and 121 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 136 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
136citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

136 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Review
  11. Review
  12. Cancers · 2026
    Review
  13. Therapeutic vaccines for NSCLC: From mechanisms to clinical translation.Chinese medical journal pulmonary and critical care medicine · 2026
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

76 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

131 authors.

Ferdinandos SkoulidisDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. fskoulidis@mdanderson.org.ORCID 0000-0002-4676-4503
Haniel A Araujo *Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Minh Truong Do *Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yu QianDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xin SunDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ana Galan-CoboDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-0988-1823
John T LeDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Meagan MontesionFoundation Medicine, Cambridge, MA, USA.ORCID 0000-0001-9155-556X
Rachael PalmerPionyr Immunotherapeutics, South San Francisco, CA, USA.
Nadine JahchanPionyr Immunotherapeutics, South San Francisco, CA, USA.
Joseph M JuanD2G Oncology, Mountain View, CA, USA.
Chengyin MinTango Therapeutics, Boston, MA, USA.
Yi YuTango Therapeutics, Boston, MA, USA.ORCID 0000-0002-2223-337X
Xuewen PanTango Therapeutics, Boston, MA, USA.
Kathryn C ArbourDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Natalie VokesDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3766-5335
Stephanie T SchmidtDepartment of Genomic Medicine and the Institute for Data Science in Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David MolkentineDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dwight H OwenDivision of Medical Oncology, Ohio State University-James Comprehensive Cancer Center, Columbus, OH, USA.
Regan MemmottDivision of Medical Oncology, Ohio State University-James Comprehensive Cancer Center, Columbus, OH, USA.
Pradnya D PatilTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Melina E MarmarelisDivision of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Mark M AwadLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Joseph C MurraySidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-6159-7814
Jessica A HellyerDepartment of Genetics, Stanford University, Stanford, CA, USA.
Justin F GainorMassachussetts General Hospital, Boston, MA, USA.ORCID 0000-0001-8697-4081
Anastasios DimouDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Christine M BestvinaDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Catherine A ShuColumbia University, New York, NY, USA.ORCID 0000-0003-0765-7665
Jonathan W RiessUniversity of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Collin M BlakelyUniversity of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-8134-3651
Chad V PecotUNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.ORCID 0000-0002-5250-2999
Laura MezquitaDepartment of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain.
Fabrizio TabbóOspedale Michele e Pietro Ferrero, Cuneo, Italy.ORCID 0000-0001-8525-2992
Matthias SchefflerDepartment of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany.ORCID 0000-0002-9031-1368
Subba DigumarthyDepartment of Radiology, Massachussetts General Hospital, Boston, MA, USA.
Meghan J MooradianMassachussetts General Hospital, Boston, MA, USA.ORCID 0000-0002-8289-8015
Adrian G SacherPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Sally C M LauDepartment of Medical Oncology, NYU Langone Perlmutter Cancer Center, New York, NY, USA.
Andreas N SaltosDepartment of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Julia RotowLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rocio Perez JohnsonDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Corinne LiuDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tyler StewartDivision of Hematology-Oncology, University of California San Diego, La Jolla, CA, USA.
Sarah B GoldbergYale School of Medicine, New Haven, CT, USA.
Jonathan KillamNorth Shore University Hospital, Manhasset, NY, USA.
Zenta WaltherDepartment of Pathology, Yale School of Medicine, New Haven, CT, USA.
Kurt SchalperDepartment of Pathology, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0001-5692-4833
Kurtis D DaviesDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Mark G WoodcockUNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Valsamo AnagnostouSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-9480-3047
Kristen A MarroneSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Patrick M FordeSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-6925-6344
Biagio RicciutiLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Deepti VenkatramanLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Eliezer M Van AllenLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Amy L CummingsDavid Geffen School of Medicine at the University of California, Los Angeles, CA, USA.ORCID 0000-0003-0472-392X
Jonathan W GoldmanDavid Geffen School of Medicine at the University of California, Los Angeles, CA, USA.ORCID 0000-0002-4925-8243
Hiram ShaishColumbia University, New York, NY, USA.
Melanie KierIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Sharyn KatzDivision of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-9816-2291
Charu AggarwalDivision of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Ying NiTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-0338-5239
Joseph T AzokTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Jeremy SegalDepartment of Pathology, University of Chicago, Chicago, USA.
Lauren RitterhouseFoundation Medicine, Cambridge, MA, USA.
Joel W NealDepartment of Genetics, Stanford University, Stanford, CA, USA.
Ludovic LacroixInstitut Gustave Roussy, Villejuif, France.ORCID 0000-0003-2535-1010
Yasir Y ElaminDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5312-909X
Marcelo V NegraoDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8938-6699
Xiuning LeDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vincent K LamSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-1319-2588
Whitney E LewisDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-3839-8993
Haley N KempDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Brett CarterDepartment of Thoracic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jack A RothDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8955-1313
Stephen SwisherDepartment of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3080-1920
Richard LeeDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0009-0007-1319-5280
Teng ZhouDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7709-0265
Alissa PoteeteDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yifan KongDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tomohiro TakeharaDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alvaro Guimaraes PaulaDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Edwin R Parra CuentasDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9068-1636
Carmen BehrensDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ignacio I WistubaDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianjun ZhangDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7872-3477
George R BlumenscheinDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carl GayDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lauren A ByersDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-0780-2677
Don L GibbonsDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-2362-3094
Anne TsaoDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J Jack LeeDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-5469-9214
Trever G BivonaUniversity of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-5734-4128
D Ross CamidgeUniversity of Colorado Cancer Center, Denver, CO, USA.
Jhannelle E GrayDepartment of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Natasha B LeighlPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Benjamin LevySidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Julie R BrahmerSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Marina C GarassinoDepartment of Medicine, University of Chicago, Chicago, IL, USA.
David R GandaraUniversity of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Edward B GaronDavid Geffen School of Medicine at the University of California, Los Angeles, CA, USA.ORCID 0000-0001-7077-8801
Naiyer A RizviSynthekine, Menlo Park, CA, USA.ORCID 0000-0002-1134-7494
Giorgio Vittorio ScagliottiUniversity of Turin, Orbassano, Italy.ORCID 0000-0001-6646-958X
Jürgen WolfDepartment of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
David PlanchardInstitut Gustave Roussy, Villejuif, France.
Benjamin BesseInstitut Gustave Roussy, Villejuif, France.ORCID 0000-0001-5090-8189
Roy S HerbstYale School of Medicine, New Haven, CT, USA.ORCID 0000-0003-2535-5847
Heather A WakeleeDepartment of Genetics, Stanford University, Stanford, CA, USA.ORCID 0000-0003-1136-980X
Nathan A PennellTaussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-1458-0064
Alice T ShawNovartis Institute for Biomedical Research, Cambridge, MA, USA.
Pasi A JänneLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-7821-4928
David P CarboneDivision of Medical Oncology, Ohio State University-James Comprehensive Cancer Center, Columbus, OH, USA.ORCID 0000-0003-3002-1921
Matthew D HellmannAstraZeneca, Gaithersburg, MD, USA.
Charles M RudinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5204-3465
Lee AlbackerFoundation Medicine, Cambridge, MA, USA.ORCID 0000-0002-5070-1783
Helen MannAstraZeneca, Cambridge, UK.
Zhou ZhuAstraZeneca, Cambridge, UK.
Zhongwu LaiAstraZeneca, Cambridge, UK.
Ross StewartAstraZeneca, Cambridge, UK.
Solange PetersDepartment of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.ORCID 0000-0002-0412-7143
Melissa L JohnsonSarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA.ORCID 0000-0001-9874-1314
Kwok K WongDivision of Hematology & Medical Oncology, NYU Langone Perlmutter Cancer Center, New York, NY, USA.ORCID 0000-0001-6323-235X
Alan HuangTango Therapeutics, Boston, MA, USA.
Monte M WinslowD2G Oncology, Mountain View, CA, USA.ORCID 0000-0002-5730-9573
Michael J RosenD2G Oncology, Mountain View, CA, USA.
Ian P WintersD2G Oncology, Mountain View, CA, USA.
Vassiliki A PapadimitrakopoulouPfizer, New York, NY, USA.
Tina CasconeDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-3008-5407
Philip JewsburyAstraZeneca, Cambridge, UK.
John V HeymachDepartment of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jheymach@mdanderson.org.ORCID 0000-0001-9068-8942

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4M
Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
Therapeutic approaches for LKB1-deficient non-small cell lung cancerR01CA205150 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEYMACH, JOHN V., WONG, KWOK KIN · 2016 to 2020
$3.0M
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapyR01CA276917 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EDWARD B GARON · 2023 to 2026
$2.9M
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitorR01CA279452 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Seyed Javad Mirhassani Moghaddam, Ferdinandos Skoulidis · 2024 to 2026
$2.0M
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancerR01CA262469 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SKOULIDIS, FERDINANDOS · 2021 to 2025
$1.8M
NovaSeq6000S10OD024977 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, VICKI · 2018 to 2018
$995k
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016042NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA205150NCI NIH HHS R01 CA262469NCI NIH HHS R01 CA276917NCI NIH HHS R01 CA279452NCI NIH HHS T32 CA009172NIH HHS S10 OD024977
6 · The paper itself

Abstract

For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB

Indexed as

AMP-Activated Protein Kinase KinasesCTLA-4 AntigenDrug Resistance, NeoplasmImmune Checkpoint InhibitorsKelch-Like ECH-Associated Protein 1Lung NeoplasmsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenCarcinoma, Non-Small-Cell LungClinical Trials, Phase III as TopicFemaleGenes, Tumor SuppressorHumansMaleAMP-Activated Protein Kinase KinasesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humanCTLA-4 AntigenCTLA4 protein, humandurvalumabImmune Checkpoint InhibitorsKEAP1 protein, humanKelch-Like ECH-Associated Protein 1Nitric Oxide Synthase Type IISTK11 protein, humantremelimumabTumor Suppressor Proteins

Identifiers

PMID39385035
PMCPMC11560846

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.